Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.
Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.
D001682:Biological Availability; D001777:Blood Coagulation / Q000187:drug effects; D004087:Dihydroergotamine / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004727:Endothelium / Q000187:drug effects; D006493:Heparin / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000517:prevention & control*; D014680:Veins / Q000187:drug effects
D004087:Dihydroergotamine; D006493:Heparin; D008012:Lidocaine